Table 2.

Studies of hormonal therapy with double HER2 blockade in metastatic breast cancer patients.

Trial	No of patients	Phase study	Study end Point	Treatment arm	Outcome
PERTAIN	258	Randomized II	PFS	Trastuzumab AI +/– pertuzumab	PFS 18.8 months and 15.8 months p 0.0070 OS not reported
ALTERNATIVE	355	Randomized III	PFS	Trastuzumab and lapatinib and AI Trastuzumab and AI Lapatinib and AI	PFS 11 versus 5.7 months p 0.0064 (lapatinib + trastuzumab + AI versus trastuzumab + AI) median OS, 46.0 versus 40.0 months

AI, aromatase inhibitor; OS, overall survival; PFS, progression-free survival.